# Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

> **NCT06478186** · PHASE4 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 120 (estimated)

## Conditions studied

- Osteoarthritis, Knee
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** triamcinolone acetonide extended-release injectable suspension; TCA-ER
- **DRUG:** Triamcinolone Acetonide- Immediate Release;TCA-IR

## Key facts

- **NCT ID:** NCT06478186
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2026-07-16
- **Final completion:** 2026-10-16
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478186, "Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06478186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*